key: cord-0951911-5a1y5rh3 authors: Mattar, C. N.; Koh, W.; Seow, Y.; Hoon, S.; VENKATESH, A.; Dashraath, P.; LIM, L. M.; ONG, J.; Lee, R. J.; Johana, N.; Yeo, J. S.; Chong, D. S. H.; Tan, L. K.; Chan, J. K. Y.; Choolani, M.; Tambyah, P. A. title: Addressing anti-syncytin antibody levels, and fertility and breastfeeding concerns, following BNT162B2 COVID-19 mRNA vaccination date: 2021-05-25 journal: nan DOI: 10.1101/2021.05.23.21257686 sha: 618e955e93d700cba3b793e41e18af05988b688d doc_id: 951911 cord_uid: 5a1y5rh3 Objective: To determine whether antibodies against the SARS-CoV-2 spike protein following BNT162B2 (Pfizer-BioNTech) COVID-19 mRNA vaccination cross-react with human syncytin-1 protein, and if BNT162B2 mRNA enters breast milk. Methods: In this observational cohort study of female front-line workers with no history of COVID-19 infection, we amplified BNT162B2 mRNA in plasma and breast milk and assayed anti-SARS-CoV-2 neutralising antibodies and anti-human syncytin-1 binding antibodies in plasma, at early (1-4 days) and late (4-7 weeks) time points following first-dose vaccination. Results: Fifteen consented participants (mean age 40.4 years, various ethnicities) who received at least one dose of BNT162B2, including five breast-feeding women and two women who were inadvertently vaccinated in early pregnancy, were recruited. BNT162B2 mRNA, detected by amplifying part of the spike-encoding region, was detected in plasma 1-4 days following the first dose (n=13), but not 4-5 weeks later (n=2), nor was the mRNA isolated from aqueous or lipid breast milk fractions collected 0-7 days post-vaccination (n=5). Vaccine recipients demonstrated strong SARS-CoV-2 neutralising activity by at least four weeks after the first dose (n=15), including the two pregnant women. None had placental anti-syncytin-1 binding antibodies at either time-point following vaccination. Conclusions: BNT162B2-vaccinated women did not transmit vaccine mRNA to breast milk, and did not produce a concurrent humoral response to syncytin-1, suggesting that cross-reactivity to syncytin-1 on the developing trophoblast, or other adverse effects in the breast-fed infant from vaccine mRNA ingestion, are unlikely. 1 on the developing trophoblast, or other adverse effects in the breast-fed infant from vaccine mRNA ingestion, are unlikely. Vaccine hesitancy threatens to compromise global vaccination efforts with lipid nanoparticleencapsulated mRNA-based COVID-19 vaccines employed under emergency use authorisation to end the pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants. Conspiracy theories propagated through social media cast doubts over the safety of these novel vaccines for fertility and breastfeeding, 1, 2 such that 13% of unvaccinated persons in the USA believe that COVID-19 vaccination may result in infertility. 3 One such claim generating significant traction suggests that vaccine mRNA-translated antibodies -which target the SARS-CoV-2 spike protein -cross-react with human syncytin-1, resulting in infertility and pregnancy loss. Syncytin proteins, which originate from endogenous human retroviruses, are involved in gamete fusion during fertilization and normal placental development, [4] [5] [6] [7] [8] and amino acid sequence similarities between syncytin proteins and the SARS-CoV-2 spike protein S2 domain raise the possibility of cross-reacting antibodies following COVID-19 vaccination. 9 This worrying spectre of disinformation may extend to BNT162B2 mRNA persistence, with the possibility of neonatal transmission via breast milk. Affected women may opt to defer vaccination or temporarily stop breast-feeding due to the lack of data on reproductive or lactational toxicity, even though COVID-19 vaccination is not contraindicated in pregnant or breastfeeding women, or for women planning pregnancy. 10, 11 Given the enduring susceptibility of pregnant and peripartum women to COVID-19 complications, we find these trends worrying as they compound vaccine hesitancy among persons of reproductive age. 12 Although attempts have been made to correct this misinformation by mainstream news outlets and the scientific community, 2, 13 anti-vaccination pundits continue to propagate vaccine scepticism and dampen confidence in vaccine safety, even among female healthcare professionals. 14 To begin to address these issues, we investigated post-vaccination mRNA persistence and anti-syncytin-1 antibodies in plasma and breast milk in female at-risk front-line workers and vaccine recipients. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 25, 2021. Female front-line workers were approached at the National University Hospital, Singapore, to participate in this institutional review board-approved study (DSRB2012/00917) between February and April 2021. Volunteers were eligible if they were scheduled to receive BNT162B2 and consented to collection of blood and breast milk (where applicable) before and after the first dose. Data is presented according to STROBE guidelines. 15 Plasma was collected at Day 0 (pre-vaccination), 1-4 days and 4-7 weeks, while breast milk was collected within 24 hours and daily for the first week, following the first dose. Blood and expressed breast milk were centrifuged at 1500G and 3000G respectively. Plasma, aqueous and lipid factions of breast milk were flash frozen before total RNA extraction with Zymo Research Quick DNA/RNA viral kit (Zymo Research, Irvine, CA). Briefly, samples were treated with DNA/RNA shield, Proteinase K, and viral DNA/RNA buffer to bind DNA and total RNA to the Zymo-Spin™ IIC-XLR Column. DNA was removed with DNase 1, RNA eluted in RNase-free Water, checked for purity and quantified spectrophotometrically. TaqMan Primers were designed using the published mRNA sequence of BNT162B2 that was made available to the public, 16 and amplified an 87bp segment of the spike-encoding region to determine the presence of vaccine mRNA in plasma and breast milk (Table 1 ). Isolated RNA, primers and probe were added to THUNDERBIRD™ Probe One-step (Toyobo, Osaka) qRT-PCR master mix and the real time PCR protocol was run on QuantStudio™ 1 Real-Time PCR System (Applied Biosystems, Foster City, CA). Negative controls were run simultaneously using water and RNA isolated from prevaccination plasma. Positive controls were day 1 post-vaccination RNA samples. First and second strand synthesis was performed with extracted plasma RNA as input (Ovation® RNA-seq system v2 kit, NuGEN Technologies Inc, Redwood City, CA). Illumina Nextera XT DNA Library Preparation kit was used for library production and barcoding. Paired end-sequencing of 300bp read length was performed on the iSeq100 sequencer (Illumina, San Diego, CA). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Sequenced reads were aligned to human references using HISAT2 and filtered out. Remaining nonhuman reads were assembled using SPAdes. Comparative analyses with published Pfizer sequences and MT380725 were performed with MUMMER. Multiple genome alignment and visualization were done using the MUSCLE and R package ggmsa (https://github.com/YuLab-SMU/ggmsa). [17] [18] [19] [20] Anti-syncytin-1 antibody semi-quantitative ELISA Neutralizing antibodies (NAb) against SARS-CoV-2 were detected using the SARS-CoV-2 Surrogate Virus Neutralization Test Kit (GenScript, NJ). Samples and controls were pre-incubated with HRP-Receptor Binding Domain (RBD) to allow the binding of circulating NAb to HRP-RBD, and the mixture added to the capture plate (pre-coated with human angiotensin converting enzyme-2 protein). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Results are expressed as mean±SD and compared by one-way ANOVA using Tukey correction for multiple comparisons. Fifteen female at-risk front-line workers who were eligible for the vaccine, including five breast-feeding mothers and two women inadvertently vaccinated in early pregnancy, were recruited for this institutional review board-approved study (DSRB2012/00917) conducted at the National University Hospital of Singapore. No subject was previously diagnosed with COVID-19. Mean age was 40.4±12.2 years. Participants were of Malay, Indian and Chinese ethnicities. All women received two doses of BNT162B2 according to the prescribed schedule, except the two pregnant subjects who each had a single dose before pregnancy confirmation, and subsequently did not receive the second dose ( Table 2) . Plasma BNT162B2 mRNA was detected within 4 days of vaccination (n=13), including in all breastfeeding women (Ct<30, all samples, Figure 1A ,B), but no amplification was observed in either aqueous or lipid breast-milk factions (days 0-7, n=5, Figure 1B ). Early plasma samples were not obtained from the two participants with undiagnosed pregnancies at the time of vaccination as they All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. had not yet been recruited (subjects 101, 102); subsequently these two participants did not amplify plasma BNT162B2 mRNA at week 4, the only single-dose samples at this time point as the other recipients had received their second dose by week 3. High-quality non-human sequenced reads from whole transcriptome sequencing of plasma-and breast milk-extracted circulating RNA were assembled to obtain draft genomic scaffolds of 4196bp (average coverage of 162X), comparable in size to BNT162B2 mRNA, and we observed perfect alignment from 120-4077bp against the published sequence. No scaffolds greater than 2kb were obtained for pre-vaccination plasma. Multiple sequence alignment performed with GenBank sequence MT380725 (SARS-CoV-2 spike protein) demonstrated agreement at the nucleotide level ( Figure 1C ). To determine if recipients mounted the desired immune response to BNT162B2, we first analysed SARS-CoV-2 neutralising antibodies (NAb), finding negative responses at day 0-4 (post-vaccination inhibition at 14.7±4.7%), and strongly positive responses 4-7 weeks post-vaccination (inhibition at 98.7±1.2%, p<0.001, Figure 2A) , including in the pregnant women (inhibition >89.0% following a single dose). At the same time-points, anti-syncytin-1 binding activities were far below the positive control and were interpreted as negative ( Figure 2B ). Our study shows that BNT162B2-vaccinated women did not transmit vaccine mRNA to breast milk, and supports the continuation of breastfeeding which may transfer protective antibodies. 21 These data are limited by the lack of surveillance beyond one week post-vaccination. Vaccinated woman should be informed about the current absence of breastfeeding safety data. 10 Our small study is also the first to investigate anti-syncytin antibodies following BNT162B2 vaccination. Our finding that BNT162B2vaccinated women did not produce a significant antibody response to syncytin-1, despite demonstrating strong neutralising activity against SARS-CoV-2, is important because it suggests that cross-reactivity to syncytin proteins on the developing trophoblast is unlikely. This is in line with computerised basic local alignment search tool (BLAST) comparisons of published nucleotide and protein sequences which have shown very limited amino acid sequence similarity -only two 2-amino acid stretches -between syncytin-1 and the S2 domain of the SARS-CoV-2 spike protein; at least 80 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 25, 2021. ; https://doi.org/10.1101/2021.05.23.21257686 doi: medRxiv preprint continuous amino acid stretches comprising >35% sequence homology is required for cross-reactivity between proteins to occur. 4 We did not however, examine duration of mRNA persistence or the clinical significance of anti-syncytin-1 antibody levels. As such, we encourage a restrained interpretation of our findings, as post-authorisation surveillance data from the US Vaccine Adverse Event Reporting System (VAERS) highlight spontaneous miscarriage as the most common obstetric outcome after COVID-19 mRNA vaccination. 22 Longitudinal surveillance of larger numbers of reproductive-age women vaccinated pre-conception and in early pregnancy should assist in parsing the role of anti-syncytin antibodies in fertility and pregnancy. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 25, 2021. ; https://doi.org/10.1101/2021.05.23.21257686 doi: medRxiv preprint SPECIAL REPORT The ex-Pfizer scientist who became an anti-vax hero. In Book SPECIAL REPORT The ex-Pfizer scientist who became an anti-vax hero Are COVID-19 vaccines safe in pregnancy? Vaccine Hesitancy. In Book KFF COVID-19 Vaccine Monitor Syncytin-1 and its receptor is present in human gametes Syncytins expressed in human placental trophoblast Expression of Syncytin 1 (HERV-W), in the preimplantation human blastocyst, embryonic stem cells and trophoblast cells derived in vitro Syncytin 1 in the human placenta Altered expression of human endogenous retroviruses syncytin-1, syncytin-2 and their receptors in human normal and gestational diabetic placenta Exaptation of Retroviral Syncytin for Development of Syncytialized Placenta, Its Limited Homology to the SARS-CoV-2 Spike Protein and Arguments against Disturbing Narrative in the Context of COVID-19 Vaccination Information about COVID-19 Vaccines for People who Are Pregnant or Breastfeeding. In Book Information about COVID-19 Vaccines for People who Are Were pregnant women more affected by COVID-19 in the second wave of the pandemic? The Lancet 2021 No, the COVID-19 vaccine doesn't cause infertility in women The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype MUSCLE: a multiple sequence alignment method with reduced time and space complexity SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women Meaney-Delman and C. D. C. v.-s. C.-P. R. Team. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons This study was funded by National University of Singapore IRB Appointment Research Fund to PAT and National Medical Research Council, Singapore COVID-19 Gap Funding (COVID19FR3-0090) to WK,YS, SH.